STAT3 and prostate carcinoma: Targeting miR-375 with e-375i could inhibit prostate cancer cell proliferation, migration, and invasion, and promote cell apoptosis and enzalutamide drug sensitivity in prostate cancer via down-regulating STAT3 expression by up-regulating PTPN4 expression (105).